Junshi Biosciences Announces Acceptance by the NMPA of Supplemental New Drug Application for Toripalimab Combined with Chemotherapy for The First-Line Treatment of Nasopharyngeal Carcinoma
–the 3rd sNDA for Toripalimab in China SHANGHAI, China, Feb. 19, 2021 (GLOBE NEWSWIRE) —…